Benmelstobart plus anlotinib showed longer progression-free survival than pembrolizumab plus placebo and no unexpected safety signals were reported, suggesting benmelstobart plus anlotinib as a potential first-line option in driver gene-negative, PD-L1-positive, advanced NSCLC. Longer term follow-up is needed to establish effects on overall survival.
[Articles] Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
The Lancet Oncology | | Hua Zhong, Jing Wang, Runxiang Yang, Yongzhong Luo, Wei Zuo, Wei Zhang, Chao Xie, Qingshan Li, Qiang Liu, Xingxiang Xu, Qiming Wang, Yan Yu, Yongxing Chen, Tienan Yi, Xuhong Min, Jinsheng Shi, Jian Yang, Hongmei Sun, Hualin Chen, Huaqiu Shi, Junzhen Gao, Jianhua Shi, Bo Zhang, Tianqing Chu, Kai Li, Baohui Han, CAMPASS Investigators
Topics: lung-cancer, blood-cancer, immunotherapy, clinical-trials, research